Davern Capital Partners
Latest statistics and disclosures from Davern Capital Partners's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002003147
Tip: Access up to 7 years of quarterly data
Positions held by Davern Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Davern Capital Partners
Davern Capital Partners holds 14 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Pfizer (PFE) | 16.4 | $51M | 2.0M | 24.90 |
|
|
| Regeneron Pharmaceuticals (REGN) | 13.1 | $41M | 52k | 771.87 |
|
|
| Biontech Se Sponsored Ads (BNTX) | 11.4 | $35M | 371k | 95.20 |
|
|
| Royalty Pharma Shs Class A (RPRX) | 10.5 | $33M | 841k | 38.64 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 9.7 | $30M | 36k | 840.95 |
|
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 7.4 | $23M | 1.1M | 21.74 |
|
|
| Roivant Sciences SHS (ROIV) | 7.2 | $22M | 1.0M | 21.70 |
|
|
| Ionis Pharmaceuticals (IONS) | 6.1 | $19M | 239k | 79.11 |
|
|
| Natera (NTRA) | 5.8 | $18M | 79k | 229.09 |
|
|
| Eli Lilly & Co. (LLY) | 2.9 | $8.9M | 8.3k | 1074.68 |
|
|
| Miragen Therapeutics (VRDN) | 2.6 | $8.1M | 262k | 31.12 |
|
|
| Mineralys Therapeutics (MLYS) | 2.5 | $7.6M | 211k | 36.29 |
|
|
| Cg Oncology (CGON) | 2.2 | $6.7M | 162k | 41.52 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 2.1 | $6.5M | 49k | 134.85 |
|
Past Filings by Davern Capital Partners
SEC 13F filings are viewable for Davern Capital Partners going back to 2025
- Davern Capital Partners 2025 Q4 filed Feb. 13, 2026